文献速递心力衰竭与心肌病心律失常

冠状窦神经肽Y水平与稳定性慢性心力衰竭患者不良结局的关系

Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure.
PubMed 文献 · JAMA Cardiol · 2020-01-01

本研究为单中心前瞻性观察队列,纳入2013至2015年接受心脏再同步治疗装置植入的105例稳定性心力衰竭患者,检测冠状窦血神经肽Y水平并随访。校正GFR、年龄和LVEF后,冠状窦NPY≥130 pg/mL与无事件生存率显著降低相关,提示NPY可能参与慢性心衰不良结局。

要点

  • 稳定性慢性心衰患者冠状窦NPY水平与eGFR、NT-proBNP及左室舒张末径相关,与LVEF和CRT反应无关。
  • 校正GFR、年龄和LVEF后,冠状窦NPY≥130 pg/mL患者无事件生存风险显著增高(HR 9.5,95%CI 2.92-30.5,P<.001)。
  • 心衰患者星状神经节NPY蛋白表达降低而mRNA水平相似,提示交感神经元NPY释放增加可能是冠状窦NPY升高的机制。

核心结论

  • 稳定性慢性心衰接受CRT的患者中,冠状窦NPY水平可能与不良结局相关,且不依赖于CRT反应。
  • 交感神经元NPY释放增加可能是慢性心衰患者冠状窦NPY水平升高的机制。

研究设计与样本

  • 单中心、三级医院前瞻性观察队列研究,纳入2013至2015年接受择期心脏再同步治疗装置植入的稳定性心衰患者105例(平均年龄68±12岁,男82例占78%,平均LVEF 26%±7%)。
  • 采集冠状窦血样检测NPY,并收集心衰患者及对照器官捐献者的星状神经节进行分子分析。

主要发现

  • 冠状窦NPY平均水平为85.1±31 pg/mL。
  • 双变量分析显示冠状窦NPY与eGFR(rs=-0.36,P<.001)、NT-proBNP(rs=0.33,P=.004)及左室舒张末径(rs=-0.35,P<.001)相关,与年龄、LVEF、功能状态或CRT反应无关。
  • 校正GFR、年龄和LVEF后,冠状窦NPY≥130 pg/mL对无事件(死亡、心脏移植或左室辅助装置)生存的HR为9.5(95%CI 2.92-30.5,P<.001)。
  • 免疫组化显示心衰患者星状神经节NPY蛋白显著低于对照(13.7±7.6 vs 31.4±3.7,P<.001),而定量PCR显示mRNA水平与对照相似。

关键数值与推荐

  • 冠状窦NPY≥130 pg/mL作为不良结局风险增高的切点。
  • 主要复合终点为心衰住院、死亡、原位心脏移植和左室辅助装置植入。

临床怎么用

  • 对于稳定性慢性心衰接受CRT的患者,冠状窦NPY水平可能有助于识别不良结局高风险人群,但需进一步研究确认。
  • NPY升高与肾功能、NT-proBNP和左室扩大相关,解读时应结合这些临床指标。

局限性

  • 单中心观察性研究,样本量有限(105例),结果需外推验证。
  • 冠状窦NPY与结局的关联不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chronic heart failure (CHF) is associated with increased sympathetic drive and may increase expression of the cotransmitter neuropeptide Y (NPY) within sympathetic neurons. OBJECTIVE: To determine whether myocardial NPY levels are associated with outcomes in patients with stable CHF. DESIGN, SETTING, AND PARTICIPANTS: Prospective observational cohort study conducted at a single-center, tertiary care hospital. Stable patients with heart failure undergoing elective cardiac resynchronization therapy device implantation between 2013 and 2015. MAIN OUTCOMES AND MEASURES: Chronic heart failure hospitalization, death, orthotopic heart transplantation, and ventricular assist device placement. RESULTS: Coronary sinus (CS) blood samples were obtained during cardiac resynchronization therapy (CRT) device implantation in 105 patients (mean [SD] age 68 [12] years; 82 men [78%]; mean [SD] left ventricular ejection fraction [LVEF] 26% [7%]). Clinical, laboratory, and outcome data were collected prospectively. Stellate ganglia (SG) were collected from patients with CHF and control organ donors for molecular analysis. Mean (SD) CS NPY levels were 85.1 (31) pg/mL. On bivariate analyses, CS NPY levels were associated with estimated glomerular filtration rate (eGFR; rs = -0.36, P < .001); N-terminal-pro hormone brain natriuretic peptide (rs = 0.33; P = .004), and LV diastolic dimension (rs = -0.35; P < .001), but not age, LVEF, functional status, or CRT response. Adjusting for GFR, age, and LVEF, the hazard ratio for event-free (death, cardiac transplant, or left ventricular assist device) survival for CS NPY ≥ 130 pg/mL was 9.5 (95% CI, 2.92-30.5; P < .001). Immunohistochemistry demonstrated significantly reduced NPY protein (mean [SD], 13.7 [7.6] in the cardiomyopathy group vs 31.4 [3.7] in the control group; P < .001) in SG neurons from patients with CHF while quantitative polymerase chain reaction demonstrated similar mRNA levels compared with control individuals, suggesting increased release from SG neurons in patients with CHF. CONCLUSIONS AND RELEVANCE: The CS levels of NPY may be associated with outcomes in patients with stable CHF undergoing CRT irrespective of CRT response. Increased neuronal traffic and release may be the mechanism for elevated CS NPY levels in patients with CHF. Further studies are warranted to confirm these findings. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01949246.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Ajijola OA, Chatterjee NA, Gonzales MJ, et al. Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure. JAMA Cardiol. 2020. PMID: 31876927. doi:10.1001/jamacardio.2019.4717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。